Quest Diagnostics Incorporated·Healthcare
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Healthcare
Medical - Diagnostics & Research
55,000
1996-12-17
0.65

Capital Management Associates Inc acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 5,900 shares of the medical research company's stock, valued at approximately $1,024,000. A number of other institutional

Foster and Motley Inc. lowered its position in Quest Diagnostics Incorporated (NYSE: DGX) by 20.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,547 shares of the medical research company's stock after selling 5,015 shares during the period. Foster and

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Delta Capital Management LLC reduced its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 12.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 17,710 shares of the medical research company's stock after selling 2,600 shares during the quarter. Quest Diagnostics accounts for approximately 1.1% of

Assenagon Asset Management S.A. raised its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 346.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,949 shares of the medical research company's stock after acquiring an additional 19,361 shares during the

SECAUCUS, N.J., March 19, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens.